Jul 21, 2026 | Alternative Reimbursement Strategies, Artificial Intelligence, Forensic claims review, MedBen Rx, Survey
Health plans are projecting a 9% medical cost trend for the commercial group market in 2027 — the highest in nearly two decades, according to PwC. A rapidly emerging driver: AI-enabled documentation and coding tools. For health plans, the concern is that more detailed...
Jul 16, 2026 | MedBen Rx, Member Prescription Portal, Mobile App, Online Services, Pharmacy, Prescription, Prescription Portal
Nearly one-third of middle-aged Americans struggle with common health tasks, including remembering doctor instructions and properly following medication directions, according to new research. Simple details — when to take a medication, whether to take it with food, or...
Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
Jun 22, 2026 | Acquisition Cost Index (ACI) pricing, MedBen Rx, Pharmacy Benefits Manager (PBM), Rebates, Spread Pricing
MedBen Rx is the fastest growing division of MedBen — and for good reason. Here’s how we stack up against traditional PBMs: CORE STRENGTHS OF MEDBEN RX OVER TRADITIONAL MODELS True Transparency & Pass-Through Traditional PBMs frequently use “spread...
May 26, 2026 | Benefits preservation, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
May 4, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rebates, Rx Costs, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the effect is already clear, with...
